PDT Partners LLC Sells 3,377 Shares of Natera, Inc. (NASDAQ:NTRA)

PDT Partners LLC lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 9.9% in the fourth quarter, HoldingsChannel reports. The firm owned 30,655 shares of the medical research company’s stock after selling 3,377 shares during the period. PDT Partners LLC’s holdings in Natera were worth $4,853,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of NTRA. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera in the third quarter worth about $385,000. Franklin Resources Inc. increased its holdings in shares of Natera by 42.6% in the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after acquiring an additional 328,375 shares in the last quarter. Exome Asset Management LLC increased its holdings in shares of Natera by 20.4% in the third quarter. Exome Asset Management LLC now owns 22,450 shares of the medical research company’s stock worth $2,850,000 after acquiring an additional 3,800 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Natera by 2.9% in the third quarter. Principal Financial Group Inc. now owns 1,012,498 shares of the medical research company’s stock worth $128,537,000 after acquiring an additional 28,751 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several recent research reports. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Barclays reduced their price target on Natera from $200.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. BTIG Research reissued a “buy” rating on shares of Natera in a research report on Friday, February 28th. Finally, Morgan Stanley increased their price target on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $175.76.

Natera Trading Down 0.5 %

NTRA stock opened at $152.99 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company’s 50-day simple moving average is $147.55 and its 200 day simple moving average is $153.87. Natera, Inc. has a 52 week low of $90.88 and a 52 week high of $183.00. The company has a market capitalization of $20.68 billion, a PE ratio of -86.93 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 343 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $49,923.65. Following the sale, the insider now directly owns 156,946 shares in the company, valued at $22,843,490.30. This represents a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 495 shares of the stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $150.74, for a total transaction of $74,616.30. Following the sale, the chief financial officer now owns 76,312 shares in the company, valued at $11,503,270.88. The trade was a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 197,301 shares of company stock worth $30,325,031 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.